SOPHIA GENETICS SF -,05

Squarepoint Ops LLC lowered its position in SOPHiA GENETICS SA (NASDAQ:SOPH – Free Report) by 30.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,753 shares of the company’s stock after selling 5,886 shares during the quarter. Squarepoint Ops LLC’s holdings in SOPHiA GENETICS were worth $43,000 at the end of the most recent quarter. Other institutional investors have also recently added to or reduced their stakes in the company. Federated Hermes Inc. raised its stake in shares of SOPHiA GENETICS by 40.5% in the 4th quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock valued at $312,000 after purchasing an additional 28,819 shares in the last quarter. Dimensional Fund Advisors LP grew its position in SOPHiA GENETICS by 23.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock worth $68,000 after purchasing an additional 4,115 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of SOPHiA GENETICS by 6.5% in the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company’s stock valued at $2,180,000 after acquiring an additional 42,689 shares in the last quarter. Institutional investors and hedge funds own 31.59% of the company’s stock. SOPHiA GENETICS Stock Performance NASDAQ SOPH opened at $2.99 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. The firm has a market capitalization of $199.39 million, a price-to-earnings ratio of -2.74 and a beta of 1.00. The company’s fifty day moving average is $2.95 and its two-hundred day moving average is $3.26. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.05. SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The business had revenue of $17.78 million for the quarter, compared to the consensus estimate of $16.76 million. Equities research analysts forecast that SOPHiA GENETICS SA will post -0.96 EPS for the current year. Wall Street Analyst Weigh In Separately, BTIG Research set a $5.00 target price on shares of SOPHiA GENETICS in a report on Thursday, March 6th. Read Our Latest Research Report on SOPHiA GENETICS About SOPHiA GENETICS (Free Report) SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.» Mehr auf defenseworld.net

SOPHiA GENETICS SA. (NASDAQ:SOPH ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Conor McNamara - RBC Capital Markets Subbu Nambi - Guggenheim Operator Good morning, ladies and gentlemen, and welcome to the SOPHiA GENETICS Q1 2025 Earnings Call.» Mehr auf seekingalpha.com

SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.» Mehr auf zacks.com